Healthcare ROI and Your Cost Per Admission

Treatment center operators who treat cost per admission as a marketing line item miss where the money actually moves. The figure on the marketing dashboard is downstream of decisions made in contracting, utilization review, and discharge planning. A facility can drive acquisition cost down 30% and still lose ground if average length of stay slips by a day, if the commercial-to-Medicaid ratio shifts, or if 30-day readmissions trigger penalty exposure under programs like HRRP ¹⁶.

The cleaner framing is unit economics. Net revenue per admission equals the per-diem rate multiplied by length of stay, weighted by payer mix, minus delivery cost, minus acquisition cost, minus any value-based or readmission adjustment. Each variable has its own lever and its own source of volatility. The IPF PPS per-diem base rate sets a federal floor for psychiatric inpatient revenue ⁷. Medicaid rate floors tied to that federal benchmark determine how much of a state’s behavioral health book reimburses at policy minimums ¹. Commercial contracts and out-of-network claims sit on top of that structure.

Demand is not the constraint. Roughly one in five American adults experiences a behavioral health issue annually, and fewer than half of those with mental illness receive timely care ¹². The constraint is converting that demand into admissions that pencil out after every adjustment is applied. The rest of this analysis works through those variables in the order they hit the income statement.

Every model of cost per admission starts with the question of what a single bed day actually pays. For psychiatric inpatient care, that answer begins with the Inpatient Psychiatric Facility Prospective Payment System. CMS pays a standardized federal per-diem rate to all IPFs, adjusted upward or downward for patient age, DRG assignment, selected comorbidities, and facility characteristics like teaching status and rural location ⁷. The base rate is the anchor variable. Everything else, including state Medicaid floors, commercial contract benchmarks, and case-mix adjustments, moves relative to it.

For FFY 2024, that federal per-diem base rate was $895.63 ¹. North Carolina Medicaid built its 2024 behavioral health policy directly on top of that number, requiring local plans to reimburse inpatient behavioral health providers at or above the federal IPF PPS per-diem ¹. Operators in states with similar rate-floor mechanics can model their Medicaid book against the same anchor. In states without that linkage, the federal rate still functions as a reference point for what commercial payers can be pushed toward in contract renewals.

The trajectory matters as much as the current rate. CMS proposed a net 2.4% increase to IPF payments for FY 2026, equivalent to $70 million in aggregate, calculated as a 3.2% market-basket update offset by a 0.8% productivity adjustment ⁸. The proposal also raises adjustment factors for teaching IPFs and rural locations, which compounds favorably for operators that qualify ⁸. A 2.4% bump sounds modest until it is multiplied by ALOS and annual admission volume across a facility. On a base near $900 per diem, that increase adds roughly $21 per bed day before any case-mix or wage-index adjustment is applied.

Two implications follow directly. First, any cost-per-admission model that ignores the federal per-diem trajectory is mispricing the revenue side of the equation. Forecasting next year’s net revenue per admission against a flat reimbursement assumption understates upside in rate-floor states and overstates the urgency of cutting acquisition cost. Second, the IPF PPS structure rewards accurate documentation of comorbidities and DRG assignment more than most operators capture in their utilization review workflow ⁷. A facility running clean documentation on age and comorbidity adjustments collects materially more per bed day than one that does not, against the same federal base.

The bed-day rate is the floor. Length of stay, payer mix, and readmission exposure determine whether that floor translates into a defensible per-admission margin or a number that looks healthy on a billing report and disappears after adjustments.

Adding admissions to a facility with broken unit economics multiplies losses rather than offsetting them. The clearest illustration in the published literature comes from a multi-hospital study of 17 U.S. children’s hospitals using 2017 data, published in 2020. Pediatric mental health hospitalizations carried a median margin of $376 per day under inpatient status and a median margin of negative $453 per day under observation status, while other medical inpatient hospitalizations cleared $603 per day ¹⁰. Aggregated across all 17 hospitals, mental health and suicide attempt hospitalizations generated an estimated annual net loss of roughly $26.7 million compared with other medical admissions when inpatient and observation stays were combined ¹⁰.

The scope matters. The data is pediatric, drawn from children’s hospitals, and reflects payer mix and contracting in those specific institutions. Adult addiction treatment operators should not transpose the absolute dollar figures to their own books. The directional finding is what travels: status assignment and payer contracting can flip a behavioral health admission from contributor to drag, holding clinical activity constant.

The operational read for owners is to audit margin by status, payer, and level of care before authorizing any push on admission volume. The questions that matter:

• What percentage of admissions land in observation versus inpatient classification.
• What the realized per-diem looks like by payer after denials and downgrades.
• Which contracts are pricing below delivery cost.

Operators who run that audit before increasing marketing spend find that the highest-ROI move is often renegotiating two or three commercial contracts or tightening medical necessity documentation, not buying more leads. Volume is a multiplier, not a fix.

The level-of-care decision drives blended cost per admission more directly than any marketing channel choice. Outpatient drug-free programs have been shown to deliver the lowest cost per successfully treated abstinent case at roughly $6,300, expressed in 1990 dollars, across a comparison of four substance use treatment modalities ¹³. The dollar figure is dated and should not be used as a current price point, but the directional finding holds: clinical effectiveness across modalities differed only modestly while cost-effectiveness varied substantially ¹³. Cost per outcome is not cost per admission, and the two figures behave differently when an operator runs a continuum of care.

For opioid use disorder specifically, a 2024 modeling study estimated that buprenorphine treatment produces 1.21 QALYs gained at $19,200 per QALY versus no treatment, with methadone also sitting under common cost-effectiveness thresholds ¹⁴. Translated into operator language, MOUD-anchored outpatient and IOP admissions carry low delivery cost per episode and high clinical leverage, which makes them attractive volume even when individual per-diem is lower than residential.

The implication for blended cost per admission is direct. A facility running residential, PHP, IOP, and MOUD-supported outpatient does not have one cost per admission. It has four, each with different acquisition cost, delivery cost, ALOS, and contract structure. Blended CPA is a weighted average across the mix, and the weights shift with referral source, payer panel, and clinical acuity at intake. Operators who report a single facility-level CPA mask the variation that actually drives margin.

The operational read is to track CPA, delivery cost, and realized revenue at the level-of-care line, then optimize the mix against contract terms. An outpatient slot under a shared-savings contract with ED-diversion bonuses can outperform a residential bed under a marginal commercial contract on a per-episode contribution basis, even though the residential bed bills more gross dollars ⁹.

The economic case for SUD treatment is one of the strongest in healthcare, and most operators leave it on the table when they sit down with commercial payers and Medicaid MCOs. A legislative review of cost-offset studies cited an average direct treatment cost of $1,583 per client against a monetary benefit of $11,487, producing a 7:1 benefit-cost ratio, with the largest savings coming from reduced crime-related costs and meaningful healthcare savings layered on top ³. The scope matters: those figures come from a policy briefing summarizing analyses where benefit-cost ratios vary by population and program design, so the 7:1 number is a directional anchor for negotiation, not a guaranteed yield in any specific contract ³.

That distinction is what turns the statistic from a feel-good talking point into a contracting asset. A payer evaluating a case-rate or shared-savings proposal does not care about societal ROI in the abstract. They care about whether the operator can credibly tie clinical performance to total cost of care on their book. The 7:1 ratio frames the conversation; outcome data the operator brings to the table closes it. A systematic review of SUD treatment economics found one cited intervention generating $14,615 in 12-month economic benefit per participant, largely from reduced criminal justice and accident-related costs ¹⁵. Operators who track post-discharge outcomes, ED utilization, and readmission rates by referral cohort can pair those internal numbers with the published evidence base when proposing rate increases, performance corridors, or downside-risk arrangements that include diversion bonuses ⁹.

Acquisition cost belongs at the end of the equation, not the beginning. An operator who optimizes CPA against an unknown net revenue per admission is solving for a number whose denominator floats. The sequence that holds up under scrutiny runs the other direction:

1. Anchor the realized per-diem against the federal IPF PPS structure and any rate-floor linkage in the operating state ^{1, 7}.
2. Establish ALOS and payer mix actuals by level of care.
3. Price in readmission and value-based exposure.
4. Back into how much acquisition cost the remaining contribution margin can absorb ¹⁶.

That sequencing changes which marketing levers matter. A facility with a clean inpatient classification mix and Medicaid rate-floor protection can absorb a higher CPA on commercial admissions because the contribution margin per admission is materially larger. A facility running observation-heavy stays under marginal commercial contracts cannot, regardless of how efficient the marketing channel looks in isolation. The same $400 CPA can be a bargain or a loss depending on which book of business it feeds.

Conversion rate is the lever that moves CPA without spending more on media. Behavioral health demand is not the bottleneck; roughly one in five American adults experiences a behavioral health issue annually, and fewer than half of adults with mental illness receive timely care ¹². The bottleneck is the path from inquiry to verified admission. Admissions scripting that qualifies against contract terms, VOB workflows that close on the first call, and intake handoffs that prevent drop-off all compress CPA at constant spend. Conversion rate optimization pulls more admissions out of the same top of funnel, which is the only sustainable way to lower CPA without sacrificing payer mix quality.